WallStreetZenWallStreetZen

NASDAQ: TRML
Tourmaline Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TRML

Based on 6 analysts offering 12 month price targets for Tourmaline Bio Inc

Min Forecast
$25.00+53.8%
Avg Forecast
$49.33+203.49%
Max Forecast
$70.00+330.64%

Should I buy or sell TRML stock?

Based on 6 analysts offering ratings for Tourmaline Bio Inc.

Strong Buy
Strong Buy
2 analysts 33.33%
Buy
4 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TRML's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TRML as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their TRML stock forecasts and price targets.

TRML stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-23
lockedlocked$00.00+00.00%2025-03-14
lockedlocked$00.00+00.00%2025-03-14
lockedlocked$00.00+00.00%2025-02-24
lockedlocked$00.00+00.00%2024-12-11
BMO Capital
Top 14%
87
BuyInitiates Coverage On$50.00+207.60%2024-12-06

1 of 1

Forecast return on equity

Is TRML forecast to generate an efficient return?

Company
-40.49%
Industry
146.26%
Market
80.85%
TRML's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TRML forecast to generate an efficient return on assets?

Company
-39.32%
Industry
36.38%
TRML is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TRML earnings per share forecast

What is TRML's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$3.42
Avg 2 year Forecast
-$4.50
Avg 3 year Forecast
-$5.66

TRML revenue forecast

What is TRML's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$60.0M
Avg 2 year Forecast
$60.0M
Avg 3 year Forecast
$60.0M

TRML vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRML$16.26$49.33+203.49%Strong Buy
OMER$7.21$22.50+212.07%Strong Buy
CELC$11.22$28.00+149.55%Buy
DNA$7.38N/AN/A
ERAS$1.43$4.83+237.97%Strong Buy
View Top Biotech Stocks

Tourmaline Bio Stock Forecast FAQ

Is Tourmaline Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: TRML) stock is to Strong Buy TRML stock.

Out of 6 analysts, 2 (33.33%) are recommending TRML as a Strong Buy, 4 (66.67%) are recommending TRML as a Buy, 0 (0%) are recommending TRML as a Hold, 0 (0%) are recommending TRML as a Sell, and 0 (0%) are recommending TRML as a Strong Sell.

If you're new to stock investing, here's how to buy Tourmaline Bio stock.

What is TRML's earnings growth forecast for 2025-2027?

(NASDAQ: TRML) Tourmaline Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Tourmaline Bio's earnings in 2025 is -$73,210,000.On average, 8 Wall Street analysts forecast TRML's earnings for 2025 to be -$87,779,954, with the lowest TRML earnings forecast at -$119,437,245, and the highest TRML earnings forecast at -$46,233,772. On average, 6 Wall Street analysts forecast TRML's earnings for 2026 to be -$115,456,003, with the lowest TRML earnings forecast at -$153,342,011, and the highest TRML earnings forecast at -$83,220,790.

In 2027, TRML is forecast to generate -$145,379,528 in earnings, with the lowest earnings forecast at -$247,350,681 and the highest earnings forecast at -$73,203,473.

What is TRML's revenue growth forecast for 2025-2027?

(NASDAQ: TRML) Tourmaline Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Tourmaline Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TRML's revenue for 2025 to be $1,541,125,740, with the lowest TRML revenue forecast at $1,541,125,740, and the highest TRML revenue forecast at $1,541,125,740. On average, 1 Wall Street analysts forecast TRML's revenue for 2026 to be $1,541,125,740, with the lowest TRML revenue forecast at $1,541,125,740, and the highest TRML revenue forecast at $1,541,125,740.

In 2027, TRML is forecast to generate $1,541,125,740 in revenue, with the lowest revenue forecast at $1,541,125,740 and the highest revenue forecast at $1,541,125,740.

What is TRML's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TRML) forecast ROA is -39.32%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is TRML's Price Target?

According to 6 Wall Street analysts that have issued a 1 year TRML price target, the average TRML price target is $49.33, with the highest TRML stock price forecast at $70.00 and the lowest TRML stock price forecast at $25.00.

On average, Wall Street analysts predict that Tourmaline Bio's share price could reach $49.33 by Apr 23, 2026. The average Tourmaline Bio stock price prediction forecasts a potential upside of 203.49% from the current TRML share price of $16.26.

What is TRML's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TRML) Tourmaline Bio's current Earnings Per Share (EPS) is -$2.89. On average, analysts forecast that TRML's EPS will be -$3.42 for 2025, with the lowest EPS forecast at -$4.65, and the highest EPS forecast at -$1.80. On average, analysts forecast that TRML's EPS will be -$4.50 for 2026, with the lowest EPS forecast at -$5.97, and the highest EPS forecast at -$3.24. In 2027, TRML's EPS is forecast to hit -$5.66 (min: -$9.63, max: -$2.85).

What is TRML's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TRML) forecast ROE is -40.49%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.